Glutathione
GSH · γ-glutamyl-cysteinyl-glycine
A major endogenous antioxidant; evidence differs sharply between oral, inhaled, topical and parenteral formulations.
Mechanism
Endogenous intracellular redox tripeptide
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Community injectable context | 200–600 mg | 200–600 mg on administration day | Two or three times weekly | Morning | Intramuscular or subcutaneous — secondary community reports | Community-reported |
| Human-study context | 600–1,200 mg | 600–1,200 mg/session | Once or twice weekly | Clinic scheduled | Intravenous; clinician administered | Trial-derived reference |
| No distinct subcutaneous schedule identified | Not established | Not established | No consistent pattern | Not established | Subcutaneous schedule not established | No consistent community schedule |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Powdered-vial arithmetic only: 1,200 mg plus 3 mL yields 400 mg/mL, so 0.10 mL equals 40 mg. This does not establish a subcutaneous schedule; injectable use remains the highest-risk route.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 200–600 mg | Two or three times weekly | 400–1800 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 1600–7200 mg | 2–6 × 1200 mg | 2–6 administrations |
| 8 weeks | 3200–14400 mg | 3–12 × 1200 mg | 2–6 administrations |
| 12 weeks | 4800–21600 mg | 4–18 × 1200 mg | 2–6 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 6–18 mL | 1–2 × 10 mL |
| 8 weeks | 9–36 mL | 1–4 × 10 mL |
| 12 weeks | 12–54 mL | 2–6 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 8–12 | 8–12 |
| 8 weeks | 16–24 | 16–24 |
| 12 weeks | 24–36 | 24–36 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Route and formulation matter. Biological importance does not itself prove benefit from exogenous administration.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.